Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel: T-Cell Lymphoma

Explore the latest updates and expert interviews

The Lymphoma Channel on VJHemOnc is supported by AstraZeneca, Takeda and Galapagos. The supporters have no influence over the production of the content.

Welcome to The T-Cell Lymphoma Channel

VJHemOnc brings you the latest updates in the field of T-cell lymphoma and helps to keep you up-to-date with the most exciting developments with video interviews, podcasts, and roundtable discussions with top researchers.

Discover updates across the spectrum of T-cell lymphomas including peripheral T-cell lymphoma, cutaneous T-cell lymphoma, anaplastic large cell lymphoma, and more. The T-Cell Lymphoma Channel covers all areas of research on T-cell lymphomas, speaking to experts about the latest data from key clinical trials of novel antibody-drug conjugates, CAR-T therapies, and new combination regimens.

The need to refine the definition of nodal-based lymphomas 1:18
The need to refine the definition of nodal-based lymphomas
Laurence de Leval • 27 Sep 2025
Differences between the WHO and ICC definitions of T-cell malignancies 1:52
Differences between the WHO and ICC definitions of T-cell malignancies
Laurence de Leval • 27 Sep 2025
The integration of evolving molecular insights in diagnostic algorithms for lymphoid malignancies 2:38
The integration of evolving molecular insights in diagnostic algorithms for lymphoid malignancies
Laurence de Leval • 27 Sep 2025
Key unmet needs in PTCL & the need for more research in this space 2:51
Key unmet needs in PTCL & the need for more research in this space
Tetiana Skrypets • 20 Jun 2025
Phase I trial of SGN-35C, a novel CD30-directed antibody-drug conjugate, in R/R lymphomas 5:13
Phase I trial of SGN-35C, a novel CD30-directed antibody-drug conjugate, in R/R lymphomas
Christina Poh • 20 Jun 2025
Early activity of ELA026, a pan-SIRP antibody, in patients with T-cell lymphoma 1:43
Early activity of ELA026, a pan-SIRP antibody, in patients with T-cell lymphoma
Swaminathan Iyer • 20 Jun 2025
First-in-human Phase I study of DR-01 in patients with R/R cytotoxic T-cell lymphomas 2:38
First-in-human Phase I study of DR-01 in patients with R/R cytotoxic T-cell lymphomas
Swaminathan Iyer • 20 Jun 2025
The International Prospective T-Cell Project 2.0: radiomics and total metabolic tumor volume 3:19
The International Prospective T-Cell Project 2.0: radiomics and total metabolic tumor volume
Tetiana Skrypets • 20 Jun 2025
The risk of subsequent malignancies after CD19 CAR-T for B-cell lymphoma: a retrospective analysis 2:27
The risk of subsequent malignancies after CD19 CAR-T for B-cell lymphoma: a retrospective analysis
Parastoo Dahi • 22 Apr 2025
Key challenges in the treatment of patients with PTCL 1:18
Key challenges in the treatment of patients with PTCL
Gandhi Damaj • 31 Mar 2025
The EBMT consensus guidelines for alloSCT in T-cell lymphoma 5:03
The EBMT consensus guidelines for alloSCT in T-cell lymphoma
Gandhi Damaj • 31 Mar 2025
The challenges associated with developing CAR-T products for T-cell malignancies 3:00
The challenges associated with developing CAR-T products for T-cell malignancies
Massimiliano Mazza • 26 Feb 2025
The development of a novel TRBC1-directed CAR T-cell therapy for T-cell malignancies 2:27
The development of a novel TRBC1-directed CAR T-cell therapy for T-cell malignancies
Massimiliano Mazza • 26 Feb 2025
Predicting response and survival in patients with PTCL treated with pembrolizumab and romidepsin 1:46
Predicting response and survival in patients with PTCL treated with pembrolizumab and romidepsin
Swaminathan Iyer • 9 Dec 2024
DR-01, an anti-CD94 monoclonal antibody, in the treatment of ultra-rare cytotoxic T-cell lymphomas 1:38
DR-01, an anti-CD94 monoclonal antibody, in the treatment of ultra-rare cytotoxic T-cell lymphomas
Swaminathan Iyer • 9 Dec 2024
Update on ETCTN P10500, a Phase I study of tazemetostat plus belinostat for the treatment of R/R NHL 4:05
Update on ETCTN P10500, a Phase I study of tazemetostat plus belinostat for the treatment of R/R NHL
Jennifer Amengual • 6 Dec 2024

The Lymphoma Channel on VJHemOnc is supported by AstraZeneca, Takeda and Galapagos.

The supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals